- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
N/A
Synonyms :
fluspirilene
Class :
Antipsychotics
Dosage Forms & Strengths
Intramuscular injection
2 mg
10 mg
parenteral injection
12 mg
1.5 mg
Initially, 2 mg weekly through deep intramuscular injection. The dose may be increased based on the patient's response. Maintenance dose: 1-10 mg weekly.
Safety and efficacy were not established
Refer to the adult dosing regimen
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may have an increased hyperkalemia when combined with acemetacin
may have an increasingly adverse effects when combined with acenocoumarol
may have an increased CNS depression when combined with acetazolamide
may have an increased CNS depression when combined with alfentanil
may have an increased serotonin syndrome when combined with amantadine
may have an increasingly adverse effects when combined with almotriptan
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may have an increased hyperkalemia when combined with amiloride
may have an increasingly adverse effects when combined with benzatropine
may have an increased CNS depression when combined with bupivacaine
may have an increased CNS depression when combined with bromperidol
it increases the toxicity of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may have an increasingly adverse effects when combined with cabergoline
may have an increased CNS depression when combined with cariprazine
may have an increasingly adverse effects when combined with carisoprodol
may have an increased CNS depression when combined with cetirizine
may have an increasingly adverse effects when combined with chlorpheniramine
may have an increased QTc prolongation when combined with chloroquine
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
eprosartan/hydrochlorothiazide
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of blood pressure-lowering agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the toxicity of antipsychotic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increasingly adverse effect when combined with amphetamines
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may diminish the absorption when combined
metyrosine: they may increase the toxic effect of antipsychotic agents
may decrease the therapeutic effect of each other when combined
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Could potentially amplify the neurotoxicity of antipsychotic agents
The potential for arrhythmogenic effects of mequitazine could be intensified by the presence of antipsychotic agents
Actions and spectrum:
Actions: fluspirilene is classified as a typical antipsychotic, and its main mechanism of action is believed to be related to its antagonism of dopamine receptors, particularly D2 receptors, in the brain. This antagonism helps to modulate the activity of dopamine, a neurotransmitter associated with mood, behavior, and cognition. By blocking D2 receptors, fluspirilene reduces the excessive dopamine activity that can contribute to psychotic symptoms.
Spectrum: fluspirilene is primarily indicated for the treatment of schizophrenia and other psychotic disorders. It helps to alleviate symptoms such as hallucinations, delusions, disorganized thinking, and agitation. Its antipsychotic effects are used to manage acute episodes of psychosis and may also be employed as maintenance therapy to prevent relapse.
Frequency not defined
dystonia
tardive dyskinesia
Neuroleptic malignant syndrome
GI disturbances
antimuscarinic symptoms
ECG changes
Parkinsonian symptoms
akathisia
nasal congestion
blood dyscrasias
rashes
conjunctiva
jaundice
Black Box Warning:
There is no specific black box warning associated with fluspirilene
Contraindication/Caution:
Contraindication:
Caution:
Comorbidities: